Proceedings of the National Academy of Sciences · 2009 · 202 citations · 54 references
Life SciencesGeneticsOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingHereditary Cancer SyndromesHereditary Gastrointestinal Cancer SyndromesMalignant NeoplasmsOncogenic Signaling PathwaysSignal Transduction In CancerCancer Signaling PathwaysGastrointestinal PolypsMammalian Target Of Rapamycin SignalingMtor Complex 1 RegulationMtor Complex 1 SignalingMtor SignalingMtorc1 SignalingTumor Metabolism
Peutz-Jeghers syndrome (PJS) is a familial cancer disorder due to inherited loss of function mutations in the LKB1/ STK11 serine/threonine kinase. PJS patients develop gastrointestinal hamartomas with 100% penetrance often in the second decade of life, and demonstrate an increased predisposition toward the development of a number of additional malignancies. Among mitogenic signaling pathways, the mammalian-target of rapamycin complex 1 (mTORC1) pathway is hyperactivated in tissues and tumors derived from LKB1-deficient mice. Consistent with a central role for mTORC1 in these tumors, rapamycin as a single agent results in a dramatic suppression of preexisting GI polyps in LKB1+/- mice. However, the key targets of mTORC1 in LKB1-deficient tumors remain unknown. We demonstrate here that these polyps, and LKB1- and AMPK-deficient mouse embryonic fibroblasts, show dramatic up-regulation of the HIF-1alpha transcription factor and its downstream transcriptional targets in an rapamycin-suppressible manner. The HIF-1alpha targets hexokinase II and Glut1 are up-regulated in these polyps, and using FDG-PET, we demonstrate that LKB1+/- mice show increased glucose utilization in focal regions of their GI tract corresponding to these gastrointestinal hamartomas. Importantly, we demonstrate that polyps from human Peutz-Jeghers patients similarly exhibit up-regulated mTORC1 signaling, HIF-1alpha, and GLUT1 levels. Furthermore, like HIF-1alpha and its target genes, the FDG-PET signal in the GI tract of these mice is abolished by rapamycin treatment. These findings suggest a number of therapeutic modalities for the treatment and detection of hamartomas in PJS patients, and potential for the screening and treatment of the 30% of sporadic human lung cancers bearing LKB1 mutations.
54
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Ken Inoki, Tianqing Zhu, Kun‐Liang Guan · Cell · 2003 · 3.9K citations · Full text
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Dana M. Gwinn, David B. Shackelford, Daniel F. Egan et al. · Molecular Cell · 2008 · 3.8K citations · Full text
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations
Medicine, Oncology, Chemotherapy +10
Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN
Vuk Stambolic, Akira Suzuki, José Luís de la Pompa et al. · Cell · 1998 · 2.6K citations · Full text
Cancer Cell Metabolism: Warburg and Beyond
Peggy P. Hsu, David M. Sabatini · Cell · 2008 · 2.5K citations · Full text